- Home
- JEF vs SCLXW Comparison
JEF vs SCLXW Comparison
Compare JEF & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JEF
- SCLXW
- Stock Information
- Founded
- JEF 1968
- SCLXW N/A
- Country
- JEF United States
- SCLXW United States
- Employees
- JEF N/A
- SCLXW 115
- Industry
- JEF Investment Bankers/Brokers/Service
- SCLXW Biotechnology: Pharmaceutical Preparations
- Sector
- JEF Finance
- SCLXW Health Care
- Exchange
- JEF Nasdaq
- SCLXW Nasdaq
- Market Cap
- JEF N/A
- SCLXW N/A
- IPO Year
- JEF N/A
- SCLXW N/A
- Fundamental
- Price
- JEF $42.84
- SCLXW $0.05
- Analyst Decision
- JEF Buy
- SCLXW
- Analyst Count
- JEF 3
- SCLXW 0
- Target Price
- JEF $54.00
- SCLXW N/A
- AVG Volume (30 Days)
- JEF 2.7M
- SCLXW 4.0K
- Earning Date
- JEF 03-26-2025
- SCLXW 03-07-2025
- Dividend Yield
- JEF 3.73%
- SCLXW N/A
- EPS Growth
- JEF 144.59
- SCLXW N/A
- EPS
- JEF 2.90
- SCLXW N/A
- Revenue
- JEF $6,865,419,000.00
- SCLXW $55,152,000.00
- Revenue This Year
- JEF N/A
- SCLXW N/A
- Revenue Next Year
- JEF $15.69
- SCLXW N/A
- P/E Ratio
- JEF $15.03
- SCLXW N/A
- Revenue Growth
- JEF 33.18
- SCLXW 22.02
- 52 Week Low
- JEF $39.28
- SCLXW $0.18
- 52 Week High
- JEF $82.68
- SCLXW $0.18
- Technical
- Relative Strength Index (RSI)
- JEF 34.36
- SCLXW N/A
- Support Level
- JEF $42.10
- SCLXW N/A
- Resistance Level
- JEF $45.29
- SCLXW N/A
- Average True Range (ATR)
- JEF 3.39
- SCLXW 0.00
- MACD
- JEF -0.09
- SCLXW 0.00
- Stochastic Oscillator
- JEF 21.98
- SCLXW 0.00
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.